Cargando…

Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study

Advanced biliary tract carcinomas (BTCs) are often diagnosed at an advanced/metastatic stage and have a poor prognosis. The combination of gemcitabine and oxaliplatin (GEMOX) has shown promising activity in this setting. This international phase II study evaluated the efficacy and safety of GEMOX as...

Descripción completa

Detalles Bibliográficos
Autores principales:	André, T, Reyes-Vidal, J M, Fartoux, L, Ross, P, Leslie, M, Rosmorduc, O, Clemens, M R, Louvet, C, Perez, N, Mehmud, F, Scheithauer, W
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538748/ https://www.ncbi.nlm.nih.gov/pubmed/19238628 http://dx.doi.org/10.1038/sj.bjc.6604628

Ejemplares similares

Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer
por: Harder, J, et al.
Publicado: (2006)

Treatment of Patients with Advanced Biliary Tract Cancer with Either Oxaliplatin, Gemcitabine, and Capecitabine or Cisplatin and Gemcitabine—A Randomized Phase II Trial
por: Markussen, Alice, et al.
Publicado: (2020)

Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer
por: Hezel, A F, et al.
Publicado: (2014)

Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review
por: Fiteni, Frédéric, et al.
Publicado: (2014)

Transcatheter arterial chemoembolization with gemcitabine and oxaliplatin for the treatment of advanced biliary tract cancer
por: Zhao, Qing, et al.
Publicado: (2015)

A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers
por: Goff, Laura W., et al.
Publicado: (2016)

Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
por: Chen, Xiaofeng, et al.
Publicado: (2020)

Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study
por: Demols, A, et al.
Publicado: (2006)

Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers
por: Chen, Ruijia, et al.
Publicado: (2022)

A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer
por: Suzuki, Eiichiro, et al.
Publicado: (2013)

Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer
por: Kim, Seung Tae, et al.
Publicado: (2015)

Real-World Evidence on Palliative Gemcitabine and Oxaliplatin (GemOx) Combination Chemotherapy in Advanced Biliary Tract Cancer
por: Lagenfelt, Hanna, et al.
Publicado: (2021)

A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract
por: Graham, J. S., et al.
Publicado: (2016)

Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma
por: von Delius, Stefan, et al.
Publicado: (2005)

Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer
por: Kim, Seung Tae, et al.
Publicado: (2015)

Multicentre, phase II study of gemcitabine and S‐1 in patients with advanced biliary tract cancer: TG1308 study
por: Chiang, Nai‐Jung, et al.
Publicado: (2020)

A Multicenter Phase II Trial of Gemcitabine Plus Oxaliplatin in Unresectable Gallbladder Cancer
por: Woo, Sang Myung, et al.
Publicado: (2013)

Effect of midkine on gemcitabine resistance in biliary tract cancer
por: Lu, Yongliang, et al.
Publicado: (2018)

Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancer
por: Matsuyama, Masato, et al.
Publicado: (2014)

Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer
por: Yoo, Changhoon, et al.
Publicado: (2018)

Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer
por: Ohkawa, S, et al.
Publicado: (2015)

Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial
por: Nehls, O, et al.
Publicado: (2002)

Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study
por: Siebenhüner, Alexander R., et al.
Publicado: (2018)

Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study
por: Kullmann, F, et al.
Publicado: (2009)

A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas
por: Lee, J K, et al.
Publicado: (2013)

Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial
por: Kim, Seung Tae, et al.
Publicado: (2019)

Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials
por: Wagner, A D, et al.
Publicado: (2009)

Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer
por: Cappuzzo, F, et al.
Publicado: (2005)

Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized Phase II Trial
por: Lim, Sung Hee, et al.
Publicado: (2021)

Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial
por: Ding, Kaiyang, et al.
Publicado: (2023)

Randomized phase III study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401‐ MITSUBA)
por: Ioka, Tatsuya, et al.
Publicado: (2022)

Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group
por: Ray-Coquard, I, et al.
Publicado: (2009)

Phase II study of S-1 in patients with advanced biliary tract cancer
por: Ueno, H, et al.
Publicado: (2004)

Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity
por: Kim, K-p, et al.
Publicado: (2011)

Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial
por: Valle, Juan W, et al.
Publicado: (2015)

Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study
por: Feng, Kaichao, et al.
Publicado: (2020)

Modified FOLFIRINOX as a Second-Line Treatment for Patients with Gemcitabine-Failed Advanced Biliary Tract Cancer: A Prospective Multicenter Phase II Study
por: Lee, Yong-Pyo, et al.
Publicado: (2022)

BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer
por: Nakashima, Shinsuke, et al.
Publicado: (2015)

Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review
por: Park, Joon Oh, et al.
Publicado: (2015)

Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer
por: Inoue, Hiroto, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7d23d2ks99t7tjqobtnthu6dbs